AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 282 min read$EFX

Begor Mark W sold $6.5M of EFX

Begor Mark W (CEO) sold 37,791 shares of EQUIFAX INC (EFX) at an average of $172.16 ($168.47–$175.85, $6.51M total) across 8 trades on 2026-07-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Begor Mark W
Published Jul 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EFX
Neutral
medium confidence
Mentioned
$EFX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EFXNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but the disclosure alone does not change Equifax’s earnings outlook, guidance, or risk profile.

02

Market read

A $6.51M CEO open-market sale is disclosed, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article does not provide context on total insider holdings changes over time, option exercises, or whether other executives sold/bought around the same window.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-28, covering sales dated 2026-07-24

Background

The article is an SEC Form 4 insider transaction for Equifax (EFX), reporting an open-market sale by the CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$EFXNeutralMedium confidence
Context

Equifax CEO Begor Mark W sold about 37,791 shares in an open-market sale totaling $6.51M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 open-market sale with a stated 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view.

Key entities

  • issuer
    Equifax Inc

    Subject of the Form 4 insider sale disclosure.

  • insider
    Begor Mark W

    Equifax CEO and reporting person who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EFX insider trading history →

Related articles

OCT 7
$EFXMed

How that 20-point Equifax error may have cost you thousands

Equifax agreed to a $100M settlement over a coding error that allegedly caused 20-point credit score inaccuracies for 4M consumers in 2022. The error could have affected mortgage, auto loan, and credit card rates. Affected consumers may receive $95-$280, with claims due by Dec. 28, 2026. Equifax denies wrongdoing.

finance.yahoo.com2 min
OCT 7
$EFXMed

What to do if you qualify for the Equifax error settlement

Equifax agreed to a $100M settlement over alleged misreporting of credit scores for 4M Americans between March and April 2022, according to the law firm Gibbs Mura. The error allegedly lowered scores by over 20 points, affecting loan approvals and interest rates. Equifax denies wrongdoing but will pay impacted individuals, pending final approval in 2027. Affected consumers can claim compensation by 2026.

finance.yahoo.com2 min
OCT 2
$EFXLow

You could get a payment from Equifax's $100M settlement

Equifax agreed to a $100M settlement for a 2022 class-action lawsuit alleging incorrect credit score reporting. The error affected about 4M Americans, potentially impacting loan approvals. Payments of $95-$280 are estimated for eligible claimants, with a final hearing set for 2027.

aol.com1 min
OCT 2
$EFXMed

Equifax and TransUnion shares fall on mortgage credit report rule change

Equifax (EFX) and TransUnion (TRU) shares fell 4% and 7% respectively after reports that FHFA may ease mortgage credit report rules. TransUnion trades near its 52-week low, down 27% YTD. The change could impact revenue and EBITDA for both firms. TransUnion reported strong Q2 earnings, with mixed analyst reactions to its price target. The company also faces credit scoring landscape shifts.

investing.com3 min
OCT 2
$EFXMed

Equifax (EFX) Stock Trades Up, Here Is Why

Equifax (EFX) shares rose 2.7% after Barclays cut its price target to $155 from $200, citing negative sentiment in the business services sector. Barclays maintained an Equal Weight rating. The stock later cooled to $143.41, up 2.6%. Equifax faces regulatory pressure from the FHFA's mortgage pricing grid changes and TransUnion's pricing strategy. The stock is down 33% YTD and 40.2% from its 52-week high.

financialcontent.com2 min